Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1283373rdf:typepubmed:Citationlld:pubmed
pubmed-article:1283373lifeskim:mentionsumls-concept:C0325912lld:lifeskim
pubmed-article:1283373lifeskim:mentionsumls-concept:C0753726lld:lifeskim
pubmed-article:1283373lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:1283373lifeskim:mentionsumls-concept:C1621296lld:lifeskim
pubmed-article:1283373pubmed:issue2-3lld:pubmed
pubmed-article:1283373pubmed:dateCreated1993-3-2lld:pubmed
pubmed-article:1283373pubmed:abstractTextPigeon cerebrospinal fluid was assayed for 5-HT (5-hydroxytryptamine) and catecholamine metabolites after systemic drug injection. The 5-HT1-like receptor agonists 8-hydroxy-(di-n-propylamino)tetralin (8-OH-DPAT), 5-methoxy-3(1,2,3,6-tetrahydropyridin-4-yl)1H indole (RU 24969), 1-(m-trifluoromethylphenyl)piperazine (TFMPP), and 1-(3-chlorphenyl)piperazine (mCPP) decreased levels of the 5-HT metabolite 5-hydroxyindoleacetic acid (5-HIAA) without altering other metabolites. 5-HIAA decreases occurred at doses of 8-OH-DPAT and RU 24969 that have anti-conflict effects in pigeons, whereas TFMPP and mCPP decreased 5-HIAA only at behaviorally disruptive doses. The novel compound 1-(2-methoxyphenyl)-1-(4-(2-phthalimido)butyl)piperazine (NAN-190), a putative 5-HT1A receptor antagonist, did not affect 5-HIAA, but attenuated the decreases produced by the agonists. NAN-190 and the alpha 1-adrenoceptor antagonist prazosin increased levels of the norepinephrine metabolite 3-methoxy-4-hydroxyphenylethylene glycol and had additive effects when co-administered. The rank order of potency in inhibiting [3H]8-OH-DPAT binding in pigeon cerebrum was 8-OH-DPAT = RU 24969 > NAN-190 >> mCPP > TFMPP. The results support suggestions that decreased 5-HT neurotransmission underlies the anxiolytic-like effects of 5-HT1A receptor agonists in pigeons.lld:pubmed
pubmed-article:1283373pubmed:languageenglld:pubmed
pubmed-article:1283373pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1283373pubmed:citationSubsetIMlld:pubmed
pubmed-article:1283373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1283373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1283373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1283373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1283373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1283373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1283373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1283373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1283373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1283373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1283373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1283373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1283373pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1283373pubmed:statusMEDLINElld:pubmed
pubmed-article:1283373pubmed:monthDeclld:pubmed
pubmed-article:1283373pubmed:issn0014-2999lld:pubmed
pubmed-article:1283373pubmed:authorpubmed-author:BarrettJ EJElld:pubmed
pubmed-article:1283373pubmed:authorpubmed-author:WeissmanB ABAlld:pubmed
pubmed-article:1283373pubmed:authorpubmed-author:GleesonSSlld:pubmed
pubmed-article:1283373pubmed:authorpubmed-author:SeggelM RMRlld:pubmed
pubmed-article:1283373pubmed:issnTypePrintlld:pubmed
pubmed-article:1283373pubmed:day15lld:pubmed
pubmed-article:1283373pubmed:volume229lld:pubmed
pubmed-article:1283373pubmed:ownerNLMlld:pubmed
pubmed-article:1283373pubmed:authorsCompleteYlld:pubmed
pubmed-article:1283373pubmed:pagination109-15lld:pubmed
pubmed-article:1283373pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:1283373pubmed:meshHeadingpubmed-meshheading:1283373-...lld:pubmed
pubmed-article:1283373pubmed:meshHeadingpubmed-meshheading:1283373-...lld:pubmed
pubmed-article:1283373pubmed:meshHeadingpubmed-meshheading:1283373-...lld:pubmed
pubmed-article:1283373pubmed:meshHeadingpubmed-meshheading:1283373-...lld:pubmed
pubmed-article:1283373pubmed:meshHeadingpubmed-meshheading:1283373-...lld:pubmed
pubmed-article:1283373pubmed:meshHeadingpubmed-meshheading:1283373-...lld:pubmed
pubmed-article:1283373pubmed:meshHeadingpubmed-meshheading:1283373-...lld:pubmed
pubmed-article:1283373pubmed:meshHeadingpubmed-meshheading:1283373-...lld:pubmed
pubmed-article:1283373pubmed:meshHeadingpubmed-meshheading:1283373-...lld:pubmed
pubmed-article:1283373pubmed:meshHeadingpubmed-meshheading:1283373-...lld:pubmed
pubmed-article:1283373pubmed:meshHeadingpubmed-meshheading:1283373-...lld:pubmed
pubmed-article:1283373pubmed:meshHeadingpubmed-meshheading:1283373-...lld:pubmed
pubmed-article:1283373pubmed:meshHeadingpubmed-meshheading:1283373-...lld:pubmed
pubmed-article:1283373pubmed:meshHeadingpubmed-meshheading:1283373-...lld:pubmed
pubmed-article:1283373pubmed:year1992lld:pubmed
pubmed-article:1283373pubmed:articleTitleNeurochemical effects of 5-HT1 receptor ligands in pigeons.lld:pubmed
pubmed-article:1283373pubmed:affiliationDepartment of Psychiatry, Uniformed Services University of the Health Sciences, Bethesda, MD.lld:pubmed
pubmed-article:1283373pubmed:publicationTypeJournal Articlelld:pubmed